logo-loader
CannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics director buys 100,000 shares on-market

This follows chairman Geoff Starr’s on-market share purchases last month.

dog with cannabis leaf
The company is focused on medicinal cannabis treatments for dogs and cats

CannPal Animal Therapeutics Ltd (ASX:CP1) non-executive director Robert Johnston has purchased 100,000 shares through on-market trades.

The purchase amounted to $11,911.86 and increased Johnston’s total holding in the company to 300,000 shares.

READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

CannPal intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.

The company's lead drug candidate is a cannabis-derived canine pain and inflammation medication.

Last month, CannPal received two key ethics approvals to progress the research and development of its lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal hopes to complete recruitment for both studies by mid CY2019.

Quick facts: CannPal Animal Therapeutics Ltd

Price: $0.17

Market: ASX
Market Cap: $15.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 25/6/18

2 min read